Today we announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with chemotherapy was well tolerated with encouraging and durable antitumor activity for first-line treatment of advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) in the ongoing Phase 2 clinical study. A poster with an updated data set will be presented at ASCO GI taking place in San Francisco, California and virtually on January 19-21, 2023.
Title: Zanidatamab + Chemotherapy as First Line Treatment for HER2-expressing Metastatic Gastroesophageal Adenocarcinoma (mGEA)
Lead Author: Elena Elimova, MD, MSc, Princess Margaret Cancer Center; Toronto, Ontario, Canada
Abstract Number: 347
The abstract is available on the ASCO GI website. The poster presentation will be available on January 19 at 12:00 pm PT to conference registrants on the ASCO GI conference website as well as to the general public on our website.